Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$171.37 - $283.23 $21.9 Million - $36.1 Million
-127,624 Reduced 39.32%
196,995 $52.6 Million
Q4 2023

Feb 13, 2024

BUY
$120.4 - $237.13 $39.1 Million - $77 Million
324,619 New
324,619 $75.1 Million

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.37B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Bain Capital Life Sciences Investors, LLC Portfolio

Follow Bain Capital Life Sciences Investors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bain Capital Life Sciences Investors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bain Capital Life Sciences Investors, LLC with notifications on news.